C-Jun N-terminal kinases
Overview[edit | edit source]
C-Jun N-terminal kinases (JNKs) are a group of mitogen-activated protein kinases (MAPKs) that are involved in regulating various cellular processes, including cell proliferation, apoptosis, and inflammation. JNKs are activated in response to stress stimuli, such as cytokines, ultraviolet radiation, and heat shock.
Structure and Isoforms[edit | edit source]
JNKs are encoded by three genes: MAPK8, MAPK9, and MAPK10, which produce ten different isoforms through alternative splicing. These isoforms are categorized into two main groups: JNK1, JNK2, and JNK3. JNK1 and JNK2 are ubiquitously expressed, while JNK3 is primarily found in the brain, heart, and testis.
Activation and Function[edit | edit source]
JNKs are activated by phosphorylation through the MAPK kinase (MKK) pathway. The upstream kinases, MKK4 and MKK7, phosphorylate JNKs on threonine and tyrosine residues, leading to their activation. Once activated, JNKs translocate to the nucleus where they phosphorylate transcription factors such as c-Jun, ATF2, and Elk-1.
JNKs play a critical role in the regulation of gene expression in response to stress. They are involved in the apoptotic response to DNA damage, and their activity is crucial for the immune response and inflammatory processes.
Clinical Significance[edit | edit source]
Dysregulation of JNK signaling has been implicated in various diseases, including cancer, neurodegenerative disorders, and diabetes. In cancer, JNKs can have both tumor-promoting and tumor-suppressing roles, depending on the context. In neurodegenerative diseases, such as Alzheimer's disease, JNKs contribute to neuronal death and neuroinflammation.
Research and Therapeutic Potential[edit | edit source]
Due to their involvement in numerous pathological conditions, JNKs are considered potential targets for therapeutic intervention. Inhibitors of JNKs are being investigated for their potential to treat inflammatory diseases, cancer, and neurodegenerative disorders.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD